Associated Papers
Common dihydropyrimidinase ( DPYS ) genetic variations do not predict fluoropyrimidine-related chemotherapy toxicity in a Canadian cohort.
Medwid SJ et al.
Pharmacogenetics and Genomics, 2024
Functional Characterization of 12 Dihydropyrimidinase Allelic Variants in Japanese Individuals for the Prediction of 5-Fluorouracil Treatment-Related Toxicity.
Hishinuma E et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2023
Protein domains provide a new layer of information for classifying human variations in rare diseases.
Corcuff M et al.
Frontiers in Bioinformatics, 2023
36896423 (PubMed )
Supplement: Table1.XLSX › Supplementary_Table_1
Impact of DPYD, DPYS, and UPB1 gene variations on severe drug-related toxicity in patients with cancer.
Yokoi K et al.
Cancer Science, 2020
Functional characterization of 21 allelic variants of dihydropyrimidinase.
Hishinuma E et al.
Biochemical Pharmacology, 2017
Novel single nucleotide polymorphisms of the dihydropyrimidinase gene (DPYS) in Japanese individuals.
Akai F et al.
Drug Metabolism and Pharmacokinetics, 2015
Potentially functional SNPs (pfSNPs) as novel genomic predictors of 5-FU response in metastatic colorectal cancer patients.
Wang J et al.
Plos One, 2014
25372392 (PubMed )
Supplement: pone.0111694.s006.pdf
Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity.
Loganayagam A et al.
British Journal of Cancer, 2013
Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism.
Thomas HR et al.
Pharmacogenetics and Genomics, 2007
Select a paper to view details